Voluntary Faculty
Voluntary faculty are typically clinicians or others who are employed outside of the School but make significant contributions to department programs at the medical center or at affiliate institutions.
Voluntary rank detailsMax Lataillade, MPH, DO
Assistant Clinical ProfessorAbout
Research
Publications
2024
Augmentation des lymphocytes T CD4+ et réduction générale des biomarqueurs inflammatoires indépendamment du taux de lymphocytes T CD4+ à l'inclusion pendant 240 semaines de traitement par fostemsavir (FTR) + traitement de fond optimisé (TFO) dans l'étude BRIGHTE
Pialoux G, Dyson A, Castillo-Mancilla J, Du F, Li B, Lataillade M, Tenorio A, Clark A, Prakash M, Neau D. Augmentation des lymphocytes T CD4+ et réduction générale des biomarqueurs inflammatoires indépendamment du taux de lymphocytes T CD4+ à l'inclusion pendant 240 semaines de traitement par fostemsavir (FTR) + traitement de fond optimisé (TFO) dans l'étude BRIGHTE. Médecine Et Maladies Infectieuses Formation 2024, 3: s142. DOI: 10.1016/j.mmifmc.2024.04.388.Peer-Reviewed Original ResearchModèles multivariés étendus pour identifier les facteurs prédictifs de la réponse virologique au fostemsavir dans l'étude BRIGHTE
Marcelin A, Li B, Du F, Krystal M, Clark A, Lataillade M, Tenorio A, Castillo-Mancilla J, Gartland M, Wang X. Modèles multivariés étendus pour identifier les facteurs prédictifs de la réponse virologique au fostemsavir dans l'étude BRIGHTE. Médecine Et Maladies Infectieuses Formation 2024, 3: s141-s142. DOI: 10.1016/j.mmifmc.2024.04.387.Peer-Reviewed Original Research
2023
365. Durable efficacy and robust CD4+ T-cell count improvement observed across age, race, sex, and geographic subgroups of heavily treatment-experienced people with multidrug-resistant HIV-1 after 240 weeks of fostemsavir treatment
Dyson A, Aberg J, Molina J, Cassetti I, Kozal M, Treviño-Pérez S, Latiff G, Lalezari J, Pialoux G, Li B, Prakash M, Clark A, Tenorio A, Pierce A, Lataillade M. 365. Durable efficacy and robust CD4+ T-cell count improvement observed across age, race, sex, and geographic subgroups of heavily treatment-experienced people with multidrug-resistant HIV-1 after 240 weeks of fostemsavir treatment. Open Forum Infectious Diseases 2023, 10: ofad500.435. PMCID: PMC10676856, DOI: 10.1093/ofid/ofad500.435.Peer-Reviewed Original ResearchMultidrug-resistant HIV-1T-cell countsVirologic response ratesCells/mm3Randomized cohortHIV-1Response rateBL CD4Viral loadDisease characteristicsTreatment optionsAdvanced HIV-1Current ARV regimenPlacebo-controlled periodTreatment-experienced peopleT-cell increaseLimited treatment optionsLong-term efficacyOverall response rateLow response rateBackground therapyContinuous CD4Suppressive regimensWeek 96Virologic responseEffects of the HIV‐1 maturation inhibitor GSK3640254 on QT interval in healthy participants
Zhang Y, Bush M, Yazdani P, Zhan J, Wen B, Bainbridge V, Wynne B, Joshi S, Lataillade M. Effects of the HIV‐1 maturation inhibitor GSK3640254 on QT interval in healthy participants. Pharmacology Research & Perspectives 2023, 11: e01151. PMID: 37961928, PMCID: PMC10644204, DOI: 10.1002/prp2.1151.Peer-Reviewed Original ResearchConceptsConcentration-QTc analysisHealthy participantsQT intervalNovel HIV-1 maturation inhibitorsPlacebo-adjusted changeHIV-1 treatmentHIV-1 maturation inhibitorsMoxifloxacin doseSupratherapeutic dosePlasma concentrationsRelevant effectsFridericia's formulaTreatment periodCardiac repolarizationHeart rateMaturation inhibitorsCardiac conductionCardiac parametersDay 7QT studyDoseTime pointsGSK3640254ΔΔQTcFPharmacokinetics